Market-Moving News for June 11th
$CMND
$MOLN
$OSG
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/27/2026 | $13.00 | Buy | H.C. Wainwright | |
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | ||
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink | |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | ||
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Darwin Lucas appointed President and Nicole Crowley promoted to General Counsel Everspan Group ("Everspan"), a specialty property and casualty insurance platform and wholly owned subsidiary of Octave Specialty Group, Inc. (NYSE:OSG), today announced two leadership changes to support its next phase of growth. Effective immediately, Darwin Lucas will become President, succeeding Steve Dresner, and Nicole Crowley has been promoted to General Counsel. Lucas has served as Chief Underwriting and Reinsurance Officer since 2023, a role he will continue to hold. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210484478/en/Everspan Gr
Conference Call Scheduled for February 24, 2026 Octave Specialty Group, Inc. (NYSE:OSG), a global specialty insurance firm, will release fourth quarter 2025 results on February 23, 2026, following the close of the market. Conference Call On February 24, 2026, at 8:30am (ET), Claude LeBlanc, President and Chief Executive Officer, and David Trick, Executive Vice President and Chief Financial Officer, will discuss fourth quarter 2025 results during a live conference call. A live audio webcast of the call will be available through the Investor Relations section of Octave's website, www.octavegroup.com. Participants may also listen via telephone by dialing (877) 407-9716 (Domestic) or (201
Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). These further safety data points, emerging following the successful completion of treatment in another six pati
4 - OCTAVE SPECIALTY GROUP INC (0000874501) (Issuer)
4 - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Issuer)
4 - OCTAVE SPECIALTY GROUP INC (0000874501) (Issuer)
4 - OCTAVE SPECIALTY GROUP INC (0000874501) (Issuer)
4 - OCTAVE SPECIALTY GROUP INC (0000874501) (Issuer)
H.C. Wainwright initiated coverage of Molecular Partners AG with a rating of Buy and set a new price target of $13.00
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Audit Committee Appoints Ernst & Young LLP as Auditor for the Year Ended December 31, 2026 KPMG to Remain the Auditor for the Year Ended December 31, 2025 Octave Specialty Group, Inc. (NYSE:OSG) today announced that as a result of a review process, the Audit Committee of its Board of Directors has approved the engagement of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm for the Company's fiscal year ended December 31, 2026, subject to completion of EY's client acceptance procedures and the execution of an engagement letter. KPMG LLP ("KPMG"), the Company's current independent registered public accounting firm, will continue as the Company's indepen
Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl
Conference Call Scheduled for February 24, 2026 Octave Specialty Group, Inc. (NYSE:OSG), a global specialty insurance firm, will release fourth quarter 2025 results on February 23, 2026, following the close of the market. Conference Call On February 24, 2026, at 8:30am (ET), Claude LeBlanc, President and Chief Executive Officer, and David Trick, Executive Vice President and Chief Financial Officer, will discuss fourth quarter 2025 results during a live conference call. A live audio webcast of the call will be available through the Investor Relations section of Octave's website, www.octavegroup.com. Participants may also listen via telephone by dialing (877) 407-9716 (Domestic) or (201
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve
Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de
SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Subject)